Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, Third Military Medical University, Chongqing, China.
1] Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, Third Military Medical University, Chongqing, China [2] Depeartment of State Key Laboratory of Trauma, Burns and Combined Injury, Daping Hospital and Institute of Surgery Research, Chongqing, China.
Oncogene. 2014 May 29;33(22):2888-97. doi: 10.1038/onc.2013.250. Epub 2013 Jul 1.
Liver X receptors (LXRs), including LXRα and LXRβ isoforms, have important roles in the metabolic regulation of glucose, cholesterol and lipid. Moreover, activation of LXRs also represses the expression of cyclin D1 and cyclin B1, and thus suppresses the proliferation of multiple cancer cells, but the relevant mechanism is not well known. Forkhead box M1 (FOXM1) is a proliferation-specific member of forkhead box family, which is highly expressed in proliferating normal cells and numerous cancer cells. FOXM1 directly activates transcription of cyclin D1 and cyclin B1, resulting in the enhancement of cell cycle progression and cell proliferation. However, it is unclear whether LXRs are involved in the regulation of FOXM1. In this study, we demonstrated that specific LXRs agonists downregulated expression of FOXM1, cyclin D1 and cyclin B1 in hepatocellular carcinoma (HCC) cells, which led to cell cycle and cell proliferation arrest. Knockdown of FOXM1 significantly alleviated LXRs activation-mediated cell cycle arrest and cell growth suppression. Reporter assays showed that the activation of LXRs significantly reduced the transcriptional activity of FOXM1 promoter. Electrophoretic mobility shift assay and chromatin immunoprecipitation assays demonstrated that LXRα but not LXRβ could bind to an inverted repeat IR2 (-52CCGTCAcgTGACCT-39) in the promoter region of FOXM1 gene. Moreover, the xenograft tumor growth and the corresponding FOXM1 expression in nude mice were dramatically repressed by LXRs agonists. Taken together, we conclude that LXRα but not LXRβ functions as a transcriptional repressor for FOXM1 expression. The pathway 'LXRα-FOXM1-cyclin D1/cyclin B1' is a novel mechanism by which LXRs suppress the proliferation of HCC cells, suggesting that the pathway may be a novel target for HCC treatment.
肝 X 受体(LXRs),包括 LXRα 和 LXRβ 异构体,在葡萄糖、胆固醇和脂质的代谢调节中发挥重要作用。此外,LXRs 的激活还抑制了细胞周期蛋白 D1 和细胞周期蛋白 B1 的表达,从而抑制了多种癌细胞的增殖,但相关机制尚不清楚。叉头框 M1(FOXM1)是叉头框家族中增殖特异性成员,在增殖正常细胞和许多癌细胞中高度表达。FOXM1 直接激活细胞周期蛋白 D1 和细胞周期蛋白 B1 的转录,从而增强细胞周期进程和细胞增殖。然而,LXRs 是否参与 FOXM1 的调节尚不清楚。在本研究中,我们证明了特定的 LXRs 激动剂下调了肝癌(HCC)细胞中 FOXM1、细胞周期蛋白 D1 和细胞周期蛋白 B1 的表达,导致细胞周期和细胞增殖停滞。FOXM1 的敲低显著缓解了 LXRs 激活介导的细胞周期停滞和细胞生长抑制。报告基因检测表明,LXRs 的激活显著降低了 FOXM1 启动子的转录活性。电泳迁移率变动分析和染色质免疫沉淀分析表明,LXRα 而不是 LXRβ 可以结合到 FOXM1 基因启动子区域的反向重复 IR2(-52CCGTCAcgTGACCT-39)上。此外,LXRs 激动剂显著抑制了裸鼠异种移植肿瘤的生长和相应的 FOXM1 表达。总之,我们得出结论,LXRα 而不是 LXRβ 作为 FOXM1 表达的转录抑制因子发挥作用。“LXRα-FOXM1-cyclin D1/cyclin B1”通路是 LXRs 抑制 HCC 细胞增殖的新机制,提示该通路可能成为 HCC 治疗的新靶点。